BRPI0415001A - droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo - Google Patents

droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Info

Publication number
BRPI0415001A
BRPI0415001A BRPI0415001-5A BRPI0415001A BRPI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A BR PI0415001 A BRPI0415001 A BR PI0415001A
Authority
BR
Brazil
Prior art keywords
acid
drug
active ingredient
acid containing
propyloctanoic acid
Prior art date
Application number
BRPI0415001-5A
Other languages
English (en)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0415001A publication Critical patent/BRPI0415001A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DROGA CONTENDO áCIDO (2R) -2-PROPILOCTANóICO COMO O INGREDIENTE ATIVO". A presente invenção se refere a uma droga que contém de cerca de um a cerca de cinco equivalentes de um íon de metal básico fornecido a partir de um sal de metal de um ácido fraco ou de um hidróxido de metal por equivalente do ácido (2R)-2-propiloctanóico ou o sal do mesmo; que seja útil no tratamento de doenças neurodegenerativas, opcionalmente junto com outros aditivos. A droga acima descrita é uma droga de alta concentração que apresenta um valor de pH adequado para a administração intravenosa; é altamente tolerante a mudanças de pH e permanece transparente depois de diluída para o preparo de uma infusão, desta forma permitindo a preparação de uma injeção e assim por diante, com o uso de um solvente arbitrário e/ou fluido de diluição.
BRPI0415001-5A 2003-10-03 2004-10-01 droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo BRPI0415001A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003345124 2003-10-03
PCT/JP2004/014892 WO2005032536A1 (ja) 2003-10-03 2004-10-01 (２ｒ)−２−プロピルオクタン酸を有効成分とする薬剤

Publications (1)

Publication Number Publication Date
BRPI0415001A true BRPI0415001A (pt) 2006-11-07

Family

ID=34419441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415001-5A BRPI0415001A (pt) 2003-10-03 2004-10-01 droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Country Status (21)

Country Link
US (1) US8053599B2 (pt)
EP (1) EP1669065B1 (pt)
JP (1) JP4715515B2 (pt)
KR (1) KR101144553B1 (pt)
CN (1) CN1889942B (pt)
AU (1) AU2004277826B2 (pt)
BR (1) BRPI0415001A (pt)
CA (1) CA2540670A1 (pt)
EC (1) ECSP066477A (pt)
ES (1) ES2390055T3 (pt)
IL (1) IL174655A0 (pt)
IS (1) IS8430A (pt)
MA (1) MA28142A1 (pt)
MX (1) MXPA06003533A (pt)
NO (1) NO20061460L (pt)
NZ (1) NZ546231A (pt)
RU (1) RU2388467C2 (pt)
SG (1) SG146687A1 (pt)
TW (1) TW200519080A (pt)
WO (1) WO2005032536A1 (pt)
ZA (1) ZA200602690B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
TWI462745B (zh) * 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
AU2009312235B2 (en) * 2008-11-04 2014-01-16 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CA2734284C (en) 2008-11-20 2014-01-21 Techno Guard Co., Ltd. Pyrazolone derivative formulations
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
JP2018052861A (ja) * 2016-09-29 2018-04-05 ノーベルファーマ株式会社 ホスフェニトインナトリウム注射剤
WO2020128928A1 (en) * 2018-12-19 2020-06-25 Jafari Javid Mihan A formulation for treatment of neurodegenerative and demyelinating and neuropathic disorders and a method for preparation thereof
CN110441421B (zh) * 2019-08-02 2022-09-09 聊城高新生物技术有限公司 一种高效液相色谱法测定恩他卡朋片溶出度的方法
CN112180095B (zh) * 2020-06-04 2023-10-13 三诺生物传感股份有限公司 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法
IT202000015895A1 (it) * 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla
AU2022280595A1 (en) * 2021-05-26 2023-11-09 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN113341019A (zh) * 2021-06-09 2021-09-03 江西省药品检验检测研究院 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113574T3 (es) * 1993-06-01 1998-05-01 Ono Pharmaceutical Co Derivados del acido pentanoico.
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
JP3032447B2 (ja) * 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) * 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JPH10298072A (ja) 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) * 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
JP4178405B2 (ja) * 2001-07-18 2008-11-12 小野薬品工業株式会社 脳虚血疾患治療剤

Also Published As

Publication number Publication date
TW200519080A (en) 2005-06-16
CA2540670A1 (en) 2005-04-14
NZ546231A (en) 2009-09-25
MXPA06003533A (es) 2006-06-08
ECSP066477A (es) 2007-03-29
US8053599B2 (en) 2011-11-08
NO20061460L (no) 2006-07-03
AU2004277826B2 (en) 2010-05-27
WO2005032536A1 (ja) 2005-04-14
EP1669065A1 (en) 2006-06-14
EP1669065A4 (en) 2009-12-16
JPWO2005032536A1 (ja) 2006-12-14
US20070105956A1 (en) 2007-05-10
SG146687A1 (en) 2008-10-30
EP1669065B1 (en) 2012-07-18
KR101144553B1 (ko) 2012-05-11
KR20060099525A (ko) 2006-09-19
RU2388467C2 (ru) 2010-05-10
MA28142A1 (fr) 2006-09-01
IL174655A0 (en) 2006-08-20
ES2390055T3 (es) 2012-11-06
CN1889942B (zh) 2010-12-15
AU2004277826A1 (en) 2005-04-14
IS8430A (is) 2006-04-26
RU2006114835A (ru) 2007-11-20
ZA200602690B (en) 2007-07-25
CN1889942A (zh) 2007-01-03
JP4715515B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
US20240238382A1 (en) URI Agonist/Vasodilator
Altier et al. Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine
Lawand et al. Amino acid release into the knee joint: key role in nociception and inflammation
JP7413315B2 (ja) Ｇｉｐ／ｇｌｐ１アゴニスト組成物
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
Townsend et al. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats
CA2663857C (en) Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
Martens et al. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers
CN109069590A (zh) 包含聚山梨酯80的胰岛素制剂
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
DK2662073T3 (en) Octreotide injection
ATE539761T1 (de) Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion
KR20190035927A (ko) 안구 내 투여를 위한 에피네프린-기반 안과용 조성물 및 이의 제조방법
Maisonneuve et al. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine
BR112021007083A2 (pt) tratamento de doença neurológica com zilucoplan
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo
TW201936191A (zh) 持續釋放輸送丁基原啡因之藥學組合物
US11040007B2 (en) Injection composition containing acetaminophen
Hildebrand et al. Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system
US9375407B2 (en) Dimethyl trisulfide as a cyanide antidote
US10632261B2 (en) Self-admixing disposable hypodermic needle
WO2009157010A1 (en) An intravenous drug delivery system
PT2262493E (pt) Métodos de tratamento empregando infusão contínua prolongada de belinostat
DeTolla et al. Subcutaneous Implants of Buprenorphine‐Cholesterol‐Triglyceride Powder in Mice

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]